Related Experiment Videos
Tanshinone IIA Attenuates Pulmonary Fibrosis via Dual Inhibition of JNK and Smad Signaling
Congying Guo1,2, Sheng Ai1,2, Jun Chen1,2
1State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Abstract:
This study investigated the mechanism of TGF-β1-induced Nox4 expression in pulmonary fibrosis (PF) and the anti-fibrotic effects of Tanshinone IIA (Tan-IIA). In a bleomycin-induced pulmonary fibrosis mouse model and in TGF-β1-stimulated fibroblasts, Tan-IIA attenuated fibrosis, oxidative stress, and fibroblast activation. Pharmacological inhibition revealed that the JNK/c-Jun and Smad3 pathways cooperatively mediate TGF-β1-induced expression of Nox4 and fibrotic markers (Collagen I/III, α-SMA). Tan-IIA exerted these effects by dually inhibiting the JNK/c-Jun and Smad2/3 pathways, reducing their phosphorylation and nuclear signaling, which consequently suppressed Nox4 transcription and protein expression. The combination of Tan-IIA with JNK or Smad3 inhibitors synergistically enhanced these effects. We identified a tandem c-Jun/Smad binding element in the Nox4 promoter that is critical for TGF-β1 response. Reporter assays and CUT&RUN experiments confirmed that TGF-β1-induced transcriptional activation depends on an intact c-Jun/Smad binding element and recruitment of c-Jun and Smad2/3. Moreover, Tan-IIA inhibited the enrichment of c-Jun and Smad2/3 at the Nox4 promoter. Collectively, our findings demonstrate that a c-Jun/Smad element integrates profibrotic JNK and Smad signaling to drive Nox4 expression. Tan-IIA presents a novel therapeutic strategy for fibrosis by simultaneously targeting these two key pathways, thereby mitigating Nox4-dependent oxidative stress and fibroblast activation.
Insights
Tanshinone IIA (Tan-IIA) reduces pulmonary fibrosis by inhibiting the JNK/c-Jun and Smad pathways, which control Nox4 expression. This dual inhibition mitigates oxidative stress and fibroblast activation, offering a new therapeutic strategy for fibrosis.
Area of Science:
- Molecular Biology
- Cell Biology
- Pharmacology
Background:
- Pulmonary fibrosis (PF) is a debilitating disease characterized by excessive extracellular matrix deposition.
- Transforming growth factor-beta 1 (TGF-β1) is a key mediator of fibrosis, inducing oxidative stress and fibroblast activation partly through Nox4 expression.
- Tanshinone IIA (Tan-IIA) is a natural compound with potential anti-fibrotic properties.
Purpose of the Study:
- To elucidate the mechanism of TGF-β1-induced Nox4 expression in pulmonary fibrosis.
- To investigate the anti-fibrotic effects of Tanshinone IIA (Tan-IIA).
- To determine the therapeutic potential of targeting the JNK/c-Jun and Smad pathways in PF.
Main Methods:
- Utilized a bleomycin-induced pulmonary fibrosis mouse model and TGF-β1-stimulated primary fibroblasts.
- Employed pharmacological inhibitors to dissect signaling pathways (JNK/c-Jun, Smad2/3).
- Conducted reporter assays and CUT&RUN experiments to analyze transcriptional regulation at the Nox4 promoter.
Main Results:
- TGF-β1 induces Nox4 expression and fibrotic markers (Collagen I/III, α-SMA) via cooperative activation of JNK/c-Jun and Smad3 pathways.
- Tan-IIA attenuates fibrosis, oxidative stress, and fibroblast activation by simultaneously inhibiting JNK/c-Jun and Smad2/3 phosphorylation and nuclear translocation.
- A tandem c-Jun/Smad binding element in the Nox4 promoter is essential for TGF-β1-induced transcription, and Tan-IIA disrupts c-Jun and Smad2/3 binding.
Conclusions:
- The Nox4 promoter contains a critical c-Jun/Smad binding element that integrates JNK and Smad signaling to drive profibrotic responses.
- Tan-IIA demonstrates a novel therapeutic strategy for pulmonary fibrosis by concurrently targeting the JNK/c-Jun and Smad pathways.
- Tan-IIA effectively suppresses Nox4-dependent oxidative stress and fibroblast activation, offering promise for treating fibrotic diseases.
Related Concept Videos
TGF - β Signaling Pathway
The JAK-STAT Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...